What Gene or Chromosome Is Affected by Sickle Cell Anemia?

Sickle cell anemia traces to a single mutation in the HBB gene, which encodes the beta-globin chain of hemoglobin and sits on chromosome 11. One DNA letter is swapped, and the amino acid valine replaces glutamic acid at position six of the beta-globin protein. That tiny change is enough to reshape red blood cells, clog blood vessels, and cause a lifetime of complications. But the story of this gene and how it interacts with others is richer and stranger than a single-letter typo might suggest.

The HBB Gene on Chromosome 11

The gene at the center of sickle cell disease is called HBB (short for hemoglobin subunit beta). It lives on the short arm of chromosome 11. Its job is to provide the instructions for building beta-globin, one of the protein chains that make up adult hemoglobin. Each hemoglobin molecule in a normal red blood cell contains two alpha-globin chains and two beta-globin chains, working together to carry oxygen from the lungs to every tissue in the body.

Sickle cell disease is a monogenetic disorder caused by a single base-pair point mutation in this gene, which swaps one amino acid for another in the beta-globin chain: valine takes the place of glutamic acid.¹ The resulting hemoglobin is called hemoglobin S (HbS). That single substitution changes a charged amino acid (glutamic acid, which interacts well with water) into a hydrophobic one (valine, which avoids water). Under low-oxygen conditions, this creates a sticky patch on the outside of the hemoglobin molecule, allowing HbS proteins to lock together into long, rigid fibers.

What Happens When Hemoglobin S Polymerizes

When oxygen levels drop in the tissues, HbS molecules snap together into stiff polymer chains inside red blood cells. Those fibers stretch the normally disc-shaped cell into the crescent or “sickle” shape that gives the disease its name. The distorted cells are both fragile and rigid, which leads to two core problems: they break apart easily, causing chronic anemia, and they get stuck in small blood vessels, blocking blood flow.²

This blockage, called vaso-occlusion, is the main driver of the severe pain crises that define the disease. But it is not just sickled red blood cells jamming up in capillaries. The process involves a cascade of interactions between sickled cells, white blood cells, platelets, and the walls of blood vessels. Adhesion molecules on these cells stick to the inner lining of blood vessels, amplifying inflammation and worsening the obstruction.³ Over time, repeated episodes of blocked blood flow and inflammation damage organs, including the spleen, kidneys, lungs, and brain.⁴

The blood itself behaves differently. Sickle red blood cells are stiffer than healthy cells, so the blood becomes more viscous. Under low-oxygen conditions, that viscosity rises further, and the blood loses some of its normal ability to thin out as it flows faster through narrow vessels.⁵ Researchers have developed tiny lab-on-a-chip devices that can measure these changes in stiffness, stickiness, and viscosity, opening the door to more precise monitoring of how someone’s blood behaves in real time.⁶

How Sickle Cell Disease Is Inherited

Sickle cell disease follows an autosomal recessive pattern, meaning a person needs to inherit a copy of the mutated HBB gene from each parent to develop the full disease. If you inherit just one copy of the sickle gene and one normal copy, you have what is called sickle cell trait (HbAS). People with the trait typically have no symptoms under ordinary conditions, and studies comparing oxygen delivery in people with trait versus people with normal hemoglobin have found no meaningful difference between the two groups.⁷

The most common and typically most severe form of the disease is homozygous sickle cell disease (HbSS), where both beta-globin genes carry the sickle mutation. But sickle cell disease is not one condition; it is a family of conditions. Compound heterozygous forms occur when a person inherits the sickle gene from one parent and a different beta-globin mutation from the other. The most important of these are:

• HbSC disease: The person has one sickle gene and one gene for hemoglobin C, another variant. This is the second most common form of sickle cell disease.⁸ Symptoms are generally milder than in HbSS but can still be serious.
• Sickle beta-thalassemia (HbS/β-thal): The person inherits a sickle gene and a beta-thalassemia gene that either reduces or completely eliminates beta-globin production from the other chromosome. When beta-globin production is absent (S/β0), the clinical picture resembles HbSS disease. When some beta-globin is still made (S/β+), symptoms tend to be milder.⁹
• Rare compound forms: Occasionally, the sickle gene pairs with even rarer beta-globin variants, producing severe disease that mimics HbSS.¹⁰

Other Genes That Make the Disease Milder or Worse

While HBB is the root cause, several other genes act as volume knobs, dialing disease severity up or down. The two best-studied modifiers involve fetal hemoglobin and alpha-thalassemia.

Fetal hemoglobin (HbF) is the form of hemoglobin that dominates before birth. It contains gamma-globin chains instead of beta-globin chains, so it does not include the sickle mutation and does not polymerize. After birth, a molecular switch gradually turns off gamma-globin production and turns on beta-globin. In most people, HbF drops to very low levels by about six months of age, which is why sickle cell symptoms typically emerge in the first year of life. But some people retain unusually high levels of HbF into adulthood, and they tend to have much milder disease because HbF molecules interrupt the formation of HbS polymer chains.

The key regulator of this switch is a protein called BCL11A, encoded by a gene on chromosome 2. BCL11A acts as a brake on gamma-globin production. When BCL11A is active in adult red blood cells, it keeps fetal hemoglobin suppressed. Turning down BCL11A lets fetal hemoglobin rise again, diluting the sickle hemoglobin and reducing sickling.¹¹ This insight has become the foundation for some of the most promising gene therapies now reaching patients.

Alpha-thalassemia, caused by deletions in the alpha-globin genes on chromosome 16, is the other major genetic modifier. A large systematic review and meta-analysis found that having concurrent alpha-thalassemia was consistently linked to higher hemoglobin levels, reduced markers of red blood cell destruction, and lower risks of stroke and kidney problems in people with sickle cell disease.¹² The reason is straightforward: with fewer alpha-globin chains available, each red blood cell contains less total hemoglobin, so there is less HbS to polymerize. Additional work in Congolese patients confirmed that certain alpha-globin gene arrangements were associated with fewer severe pain crises, fewer blood transfusions, and lower rates of bone damage and gallstones.¹³

The picture is not entirely rosy, though. While alpha-thalassemia clearly protects against some complications, a study of patients with both HbSS and HbSC disease found that, despite reduced red blood cell stiffness and lower transfusion needs, alpha-thalassemia did not translate into longer survival overall.¹⁴ Genetic modifiers, in other words, shift the balance of complications rather than simply making everything better.

Why the Sickle Gene Persists

A mutation this harmful should, by the logic of natural selection, have been weeded out over generations. The reason it hasn’t is malaria. In regions where falciparum malaria has historically been deadly and widespread, carrying one copy of the sickle gene offers a powerful survival advantage. Studies in West Africa have reported that sickle cell trait protects against severe malaria by roughly 90%.¹⁵

This explains the geographic distribution of the sickle gene. Global mapping shows high frequencies of the HbS allele across most of sub-Saharan Africa, the Middle East, and India, along with gene flow through historical migrations to western Europe and the eastern coast of the Americas.¹⁶ The mutation arose independently at least five times in human history in different malaria-endemic regions, a striking example of convergent evolution under pressure from a single parasite. Today, as populations have migrated worldwide, the sickle gene is found far outside malaria zones, though its highest prevalence remains in areas where malaria transmission was historically intense.

Newborn Screening and Diagnosis

Because sickle cell disease can cause life-threatening complications in infancy, early detection matters. Most high-income countries screen newborns at birth using a blood sample from a heel prick. The standard laboratory methods include high-performance liquid chromatography, capillary electrophoresis, and isoelectric focusing, all of which separate and identify the different hemoglobin types present in a baby’s blood.¹⁷

These protein-based tests are well established, but they have limitations. They can sometimes struggle to distinguish between similar compound heterozygous forms, especially in newborns whose hemoglobin profile is still dominated by fetal hemoglobin. Molecular testing that reads the DNA sequence of the globin genes directly is increasingly used as a follow-up or even a primary screen, since the genes are small and the known variants are well cataloged.¹⁸ In low-resource settings, newer point-of-care devices based on microfluidic chips are being developed to bring rapid screening to communities where traditional laboratory infrastructure is limited.⁶

Gene Therapies Targeting the Root Cause

For decades, the only disease-modifying drug approved for sickle cell disease was hydroxyurea, which works partly by boosting fetal hemoglobin. Two newer drugs, crizanlizumab and voxelotor, received accelerated FDA approval in recent years, but both were subsequently pulled from markets after post-approval data raised serious safety and efficacy concerns.¹⁹ That rocky history has intensified interest in gene therapies that address the disease at the DNA level.

The most advanced gene-editing approach targets BCL11A, the fetal hemoglobin suppressor on chromosome 2. In a landmark trial, CRISPR-Cas9 was used to disrupt BCL11A’s activity in a patient’s own blood stem cells. Those edited cells were then transplanted back after the patient’s bone marrow was cleared. More than a year later, the treated patient with sickle cell disease had high levels of fetal hemoglobin distributed throughout their red blood cells, no longer needed transfusions, and had no vaso-occlusive episodes.²⁰ This therapy, known as exagamglogene autotemcel (exa-cel), became the first CRISPR-based treatment approved by the FDA in December 2023.

Other strategies use zinc finger nucleases instead of CRISPR to target the same BCL11A enhancer, achieving similarly high rates of gene modification and large increases in fetal hemoglobin production in laboratory-grown red blood cells from treated stem cells.²¹

A complementary line of research takes a different tack entirely: instead of reawakening fetal hemoglobin, it aims to replace or suppress the sickle beta-globin directly. Lentiviral vectors can deliver an engineered anti-sickling beta-globin gene (called βAS3) into a patient’s stem cells. This synthetic gene contains three amino acid changes designed to block the contacts HbS molecules use to form fibers. One version of the vector goes further by also carrying a small RNA molecule that selectively silences the sickle gene without affecting the therapeutic gene’s expression, reducing HbS levels while increasing the protective protein.²² The anti-sickling mutations in the βAS3 protein disrupt both the side-by-side and end-to-end contacts that HbS polymers rely on, giving the engineered chain a competitive advantage for incorporation into hemoglobin molecules.²³

These gene therapies are still expensive and logistically complex, requiring chemotherapy to clear the patient’s bone marrow before reinfusion. Access remains limited in the sub-Saharan African countries where sickle cell disease is most common. But they represent a genuine shift: for the first time, treatments are correcting the genetic problem rather than managing its downstream effects.

The First “Molecular Disease”

Sickle cell anemia holds a unique place in the history of genetics. In 1949, Linus Pauling and colleagues published a paper showing that the hemoglobin from people with sickle cell disease moved differently in an electric field compared to normal hemoglobin, proving that the disease originated from an abnormal protein. It was the first time any human disease had been traced to a specific molecular defect, and the paper coined the concept of a “molecular disease.”²⁴ The exact DNA mutation was identified years later, after the genetic code was deciphered. The fact that such a dramatic disease comes from a single letter of DNA, in a single gene, on a single chromosome, made sickle cell anemia the textbook example of how small genetic changes can have sweeping biological consequences.

Today, the HBB gene is among the most thoroughly studied in the human genome. Researchers have cataloged hundreds of different mutations in it, many of which cause various forms of thalassemia or other hemoglobin disorders. The beta-globin gene cluster on chromosome 11 also contains genes for other globin chains, including the gamma-globin genes responsible for fetal hemoglobin. This physical proximity is part of why the fetal-to-adult hemoglobin switch is so tightly regulated and why manipulating it therapeutically has proven feasible. Mouse studies of the beta-globin locus have been valuable for understanding how these linked globin genes evolved and diversified, revealing that gene duplication and structural variation in the cluster are ancient features shaped by natural selection.²⁵